

***Conflict of Interest and Medical Innovation: Ensuring Integrity while
Facilitating Innovation in Medical Research
A Workshop***

June 5, 2013

**National Academy of Sciences Building
2101 Constitution Ave., N.W.
Washington, DC 20037**

Workshop Objectives:

- To articulate and clarify current conflict of interest policies
 - To examine and discuss the scope and goals of conflict of interest policies
 - To examine the effect of current conflict of interest policies on medical innovation
 - To identify best practices and potential solutions for facilitating innovation under current conflict of interest policy implementation while still ensuring scientific integrity and public trust
-

8:30–8:45 A.M.

**Welcoming Remarks and Charge to Workshop Speakers and
Participants**

Sharon F. Terry, *Roundtable Co-Chair and Workshop Chair*
President and CEO
Genetic Alliance

SESSION I: CURRENT LANDSCAPE FOR MEDICAL INNOVATION

Moderator: Allen Lichter, American Society of Clinical Oncology

8:45–9:15 A.M.

Conflict of Interest and Medical Innovation

Bernard Lo
President
Greenwall Foundation

9:15–9:45 A.M.	Enhancing the Development of Novel Medical Products and Clinical Applications Neal Cohen Vice Dean, School of Medicine Professor of Anesthesia and Perioperative Care and Medicine Director, International Medical Services University of California, San Francisco
9:45–10:15 A.M.	Developing Policies for Conflict of Interest Sally Rockey Deputy Director for Extramural Research National Institutes of Health
10:15–10:45 A.M.	Discussion with Speaker and Attendees
10:45–11:00 A.M.	BREAK

SESSION II: IMPACT OF CONFLICT OF INTEREST POLICIES ON INNOVATION

	Moderator: Bernard Lo, Greenwall Foundation
11:00–11:15 A.M.	Industry Perspectives Gabriela Lavezzari Assistant Vice President, Scientific Affairs PhRMA
11:15–11:30 A.M.	Academic Perspective Heather Pierce Senior Director, Science Policy and Regulatory Counsel AAMC
11:30–11:45 A.M.	Government Perspective Krishna Balakrishnan Senior Technology Manager, Office of Strategic Alliances National Center for Advancing Translational Sciences
11:45–12:25P.M.	Discussion with Speakers and Attendees

12:25 P.M.–1:10 P.M.

WORKING LUNCH

SESSION III: PUBLIC PERCEPTIONS OF CONFLICT OF INTEREST

Moderator: Jill Hartzler Warner, Food and Drug Administration

1:10–1:30 P.M.

Serving Public Interest and Facilitating Innovation: Portrayals of Conflict of Interest

Charles Ornstein
Senior Reporter
ProPublica

1:30–1:50 P.M.

Innovation in the Interest of Society

Mary Grealy
President
Healthcare Leadership Council

1:50–2:10 P.M.

Discussion with Speakers and Attendees

SESSION IV: BEST PRACTICES TO FACILITATE INNOVATION

Moderator: Dorit Zuk, National Institutes of Health

2:10–2:15 P.M.

FDA

Michelle T. McMurry-Heath
Associate Director for Science
Center for Devices and Radiological Health
Food and Drug Administration

2:15–2:20 P.M.

Tech Transfer

Todd Sherer
Associate Vice President for Research
Executive Director, Office of Technology Transfer
Emory University

2:20–2:25 P.M.

Industry

Paul Billings
Chief Medical Officer
Life Technologies Corporation

2:25–2:30 P.M.

Academia

Guy Chisolm
Director, Innovation Management and Conflict of Interest Program
Cleveland Clinic

2:30–2:35 P.M.

Public/Consumer/Advocate

Margaret Anderson
Executive Director
FasterCures

2:35–2:40 P.M.

Providers

Henry Brem
Harvey Cushing Professor
Chairman, Department of Neurosurgery
Professor of Neurosurgery, Ophthalmology, Oncology
and Biomedical Engineering
Johns Hopkins University School of Medicine

2:40–2:45 P.M.

Medical Professional Society

Allen Lichter
Chief Executive Officer
American Society of Clinical Oncology

2:45–3:50 P.M.

Roundtable Discussion with Speakers and Attendees

3:50–4:05 P.M.

BREAK

SESSION V: CONVERGENCE ON CONFLICT OF INTEREST

Moderator: Sharon Terry, Genetic Alliance

4:05–4:50 P.M.

Panel Discussion

Panelists:

Margaret Anderson, FasterCures

Gabriela Lavezzari, PhRMA

Allen Lichter, American Society of Clinical Oncology

Bernard Lo, Greenwall Foundation

Michelle T. McMurry-Heath, Food and Drug Administration

Heather Pierce, AAMC

SESSION VI: CONCLUSION

4:50–5:00 P.M.

CONCLUDING REMARKS

Sharon F. Terry, *Roundtable Co-Chair and Workshop Chair*

President and CEO

Genetic Alliance

5:00 P.M.

ADJOURN